WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006015426) COMPOSITIONS AND METHODS FOR ANGIOGENESIS-RELATED MOLECULES AND TREATMENTS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/015426    International Application No.:    PCT/AU2005/001188
Publication Date: 16.02.2006 International Filing Date: 09.08.2005
IPC:
C12N 15/11 (2006.01)
Applicants: BIONOMICS LIMITED [AU/AU]; 31 Dalgleish Street, Thebarton, S.A. 5031 (AU) (For All Designated States Except US).
KREMMIDIOTIS, Gabriel [AU/AU]; (AU) (For US Only).
LAVRANOS, Tina, Christine [AU/AU]; (AU) (For US Only).
LESKE, Annabell, Frances [AU/AU]; (AU) (For US Only)
Inventors: KREMMIDIOTIS, Gabriel; (AU).
LAVRANOS, Tina, Christine; (AU).
LESKE, Annabell, Frances; (AU)
Agent: GRIFFITH HACK; 509 St Kilda Road, Melbourne, VIC 3004 (AU)
Priority Data:
2004904441 09.08.2004 AU
2005902344 10.05.2005 AU
Title (EN) COMPOSITIONS AND METHODS FOR ANGIOGENESIS-RELATED MOLECULES AND TREATMENTS
(FR) COMPOSITIONS ET PROCEDES POUR MOLECULES LIEES A L’ ANGIOGENESE ET TRAITEMENTS
Abstract: front page image
(EN)Short interfering RNA (siRNA) molecules which modulate the expression of an angiogenesis-related gene by RNA interference are described. Short hairpin RNA (shRNA) molecules comprising said siRNA molecules are also described. These molecules can target all, or specific, isoforms of the gene. The use of these molecules and of isoforms of the gene for the treatment and diagnosis of angiogenesis-related disorders is also described.
(FR)La présente invention décrit les molécules de petits fragments d’ARN interférant (siRNA) qui modulent l’expression d’un gène lié à l’angiogénèse par interférence de l’ARN. Elle décrit également les molécules d’ARN en petites épingles à cheveux (shRNA) comprenant lesdites molécules de siRNA. Ces molécules peuvent cibler tous les isoformes ou des isoformes spécifiques du gène. Il est également décrit l’utilisation de ces molécules et d’isoformes du gène pour le traitement et le diagnostic de troubles liés à l’angiogénèse.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)